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It has long been recognized that rheumatoid arthritis (RA), 
even when well treated, may have periods of exacerbation 
and improvement. Both patients and their clinicians have 
called these periods of worsening an RA “flare”. Some of these 
exacerbations are short-lived, necessitating minimal or no 
intervention, while others may be of a sufficient severity to 
require changes in medications that address the symptoms and 
loss of function that accompany a flare. While this phenomenon 
is well recognized by both physicians and patients, there 
are no generally agreed-upon parameters to define disease 
worsening, to characterize its severity, or to describe its onset 
and duration.
RA patient care has undergone important change in the 
last two decades, with the ability to diagnose disease earlier, 
the recognition of early joint damage as leading to disability, 
and the ensuing advent of effective treatment paradigms often 
including biological therapies. With the increasingly common 
use of aggressive and earlier combination disease-modifying 
antirheumatic drug (DMARD) treatment, the numbers of 
patients experiencing substantial improvement – either 
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“Flare” is a term that is commonly used by both patients and clinicians to describe a debilitating worsening of 
symptoms. While conceptually recognized, there is limited formative research to identify the measures of clinical 
characteristics or other variables that define this state. As treatment strategies and medications become available 
to achieve low levels of disease activity and remission, measures to guide tapering of medications, or re-treatment 
when disease appears to worsen, are needed to facilitate clinical trials and to move these treatment approaches from 
clinical trials to clinical practice. While several different definitions of flare or disease worsening have been used in 
clinical studies, the validity of these to guide changes in treatment has not been tested. Moreover, the experience 
of RA patients has not been adequately evaluated to assure understanding of features of disease worsening that are 
most important, their magnitude, and/or their temporal occurrence and duration, which then cause a patient to seek 
change in treatment. An Outcome Measures in Rheumatology Clinical Trials (OMERACT) initiative, which includes 
researchers, clinicians, and patients, is now underway to evaluate these aspects of disease worsening in RA. Timely, 
data-driven completion of this project with an agreed definition of RA flare is intended to facilitate clinical trials, 
observational clinical research, and ultimately enhance clinical care. Int J Adv Rheumatol 2009;7(3):85–91.
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remission or very low disease activity – is increasing. Recent 
clinical trials are reporting data for “remissions” by various 
criteria (e.g. 28-joint count Disease Activity Score [DAS28], 
Clinical Disease Activity Index [CDAI], and Simplified Disease 
Activity Index [SDAI]), as well as high magnitude levels of 
improvement from the initial treatment baseline, such as the 
90% improvement in American College of Rheumatology 
criteria for RA (ACR90) measure [1]. The Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) working group have 
an ongoing effort to develop a definition for a minimal disease 
activity state [2,3], and the American College of Rheumatology 
(ACR) and European League Against Rheumatism (EULAR) are 
working to develop a revised definition of remission that can be 
used for both clinical trials and clinical practice [4]. With such 
outcomes now possible, patients and clinicians are increasingly 
interested in guidelines for tapering medications to maintain 
a low disease activity state (Table 1). However, developing 
study designs to test or compare such strategies is limited 
because there is no standard definition for disease worsening 
(often characterized as “flare”). The development of a standard 
definition could also enable clinical treatment decisions, using 
objective criteria to evaluate RA “flares” for proactive control of 
disease and enhanced patient management.
importance of defining  
flares in clinical practice
Clinicians caring for patients with RA appreciate the temporal 
fluctuations of disease activity, which may vary in magnitude 
and impact for the patient. Even patients who are well 
controlled describe “good days” and “bad days”. The term 
flare has entered the vernacular to describe various levels of 
disease worsening by both patients and physicians, but there 
is no commonly accepted understanding of the constituents of 
a flare. Some clinicians believe this to be an increase in joint 
swelling and tenderness, while others follow a rise in acute 
phase reactants to detect a “flare”; others use characteristics 
of disease such as patient or physician global assessments to 
“document” worsening. Confusing this issue further, it may 
be that worsening in a single joint as well as a mild worsening 
in multiple joints could be interpreted as a flare. Thus, there 
is heterogeneity in what may constitute a flare of disease, but 
more importantly, the decision to act upon these factors in 
terms of specific interventions also varies widely from patient 
to patient and practitioner to practitioner. Finally, a goal of 
effective treatment should be to decrease or eliminate flares 
or the frequency of periods of disease worsening, as these 
may result in a progressive loss of function and time lost from 
regular daily activities, including work.
While some might view decision-making based on 
individual characteristics as part of the “art” of medicine, 
approaches vary widely, and there are no best practices. Because 
many patients are not cared for by rheumatologists on an 
ongoing basis, the provision of some guidance for practitioners 
and patients may be helpful to set thresholds for contacting 
the rheumatologist for intervention. There is also an important 
aspect of understanding flares in all their different perspectives, 
to assist in management guidelines for specific therapies.
Interventions used to treat a flare range from adding, 
switching, or increasing the dose of medications including 
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
DMARDs, and biologics. If a patient comes for a visit with 
a mild degree of worsening in disease activity, it must be 
determined whether such a change represents part of an 
expected oscillation of RA disease activity that could be 
managed with non-pharmacological intervention, or whether 
the magnitude or duration of worsening mandates a more 
substantial intervention. Additional considerations when 
evaluating a flare are the severity of a symptom or symptom 
complex, and the persistence of worsening rather than simply 
an assessment at a single point in time. Changes in treatment 
regimens, in particular biologic regimens, may substantially 
increase cost (and possibly risk) due to premature repeat 
administration, early dose escalation, or changes in frequency 
of dosing. Thus, it becomes increasingly important to establish 
both a conceptual and operational framework to provide 
guidance for such decisions.
Over the last decade, substantial improvements in 
outcomes in patients with RA, both as a result of earlier 
DMARD intervention and due to the introduction of more 
potent regimens of combinations of DMARDs, including 
biological agents, have been seen. Detectable differences, while 
once an acceptable goal of therapy, have been replaced by an 
Table 1. Examples of the use of a definition of RA flare.
usefulness in Clinical trials
Evaluating duration of effect • 
Evaluating changes in drug doses, frequencies, or strategies  • 
for tapering 
 Evaluating the need for dose escalation or re-administration  • 
Evaluating the efficacy of concomitant medications (e.g. steroids, 
NSAIDs) to treat increased or oscillating symptoms 
Capturing and quantifying certain “adverse events” (e.g. “RA • 
Flare”, lack of efficacy withdrawals) 
usefulness in Clinical Practice
Deciding when to increase dose or add or change drugs based on • 
uniform definition of disease worsening (e.g. RA “flare”) 
Developing guidance to re-administer periodically dosed medication • 
Defining what is an “acceptable” degree of disease oscillation, • 
amount, and duration, incorporating the patient’s perspective 
Detecting the earliest or prodromal signs and symptoms of • 
impending “flare” to potentially avert severe disease worsening 
Improving evaluation and communication of patient reported • 
outcomes and self-management strategies to limit the occurrence 
of disabling disease worsening 
NSAIDs: nonsteroidal anti-inflammatory drugs; RA: rheumatoid arthritis.
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expectation for significant, clinically meaningful improvements 
of disease, initially described for clinical trials but now clearly 
playing out in clinical practice. Now, the goals of therapy are 
to achieve a state of remission or minimally active disease, and 
these endpoints – once used only for clinical trials – are now 
being applied to clinical practice (e.g. DAS28 remission) [5–8].
“There is no commonly accepted 
understanding of the constituents of a flare”
With the ability to induce low activity states, practitioners 
and patients ask the questions of “how much?” and “for 
how long?” Once an acceptable degree of disease control is 
achieved, many patients begin to self-taper medications, and 
physicians also begin to modulate therapy. Yet these decisions 
are largely guided by individual factors, and there is a very 
limited literature to provide guidance for tapering medications. 
Furthermore, the decision of which drug to taper is variable and 
additional questions continue to emerge: does one initially taper 
corticosteroids, taper methotrexate, remove other combination 
DMARDs, or taper biologic dose or frequency? If such a change 
in therapy is introduced, how long should one wait before 
beginning the next step down? Which outcome variables 
are most appropriate to determine how much worsening is 
allowable before stepping therapy back up?
There is also limited information or recommendations 
regarding repeat administration of periodically administered 
medications with a variable infusion schedule, such as 
rituximab. Recently, consensus-based recommendations have 
been provided regarding retreatment with rituximab for patients 
in DAS28 >0.6 “or an equivalent change in disease activity”, or 
residual disease defined by DAS28 as high activity (>5.1) [9]. 
While such consensus-based definitions may be helpful, the 
validity of such statements needs to be tested in both clinical 
trials databases as well as in clinical practice cohorts.
How can insights  
from patients help?
The above discussion has largely focused on the physician–
practitioner perspectives of disease worsening. Patient-reported 
outcomes are increasingly recognized as a critical component 
of patient assessment in clinical trials and clinical practice. 
Minimal detectable differences (MDD) and minimal clinically 
important differences (MCID) in terms of global assessments, 
pain, the Health Assessment Questionnaire (HAQ), and health-
related quality of life (HRQoL) by Short Form-36 (SF-36) have 
been established for improvement and for worsening. These 
established differences indicate that patients perceive worsening 
sooner, with less change than for improvement in each measure. 
These instruments also reflect the effect of confounding factors 
such as duration of disease and number of prior DMARDs. 
Whereas the HAQ may show less improvement when more 
impairment in physical function is present, other instruments 
such as SF-36 may show more change in those domains with 
the lowest scores at baseline [10]. Patients perceive and report 
their HRQoL relative to severity of disease at start of treatment 
and magnitude of improvement, and possibly other factors. 
Thus a patient’s tolerance for a small degree of worsening may 
differ given a longer term understanding that small fluctuations 
may be part and parcel to the disease experience [11]. 
The involvement of patients has been an imperative part 
of the OMERACT process. Patient representatives have had 
an important role in helping professionals to understand the 
totality of the disease experience. The importance of this 
perspective has been seen in the recognition that fatigue is a 
critical domain in RA that was not adequately captured in many 
historical cohorts or clinical trials [12]. From a patient-focused 
perspective, many new questions emerge regarding worsening 
of disease. These are poorly studied and include the following: 
What is a “flare”•	 ? 
Does this term capture the experience of worsening•	 ? 
Are there different types of flares•	 ? 
How long must symptoms persist and how severe must •	
symptoms become until worsening requires intervention? 
What types of self-management strategies are used•	 ? 
How effective are different medical interventions in •	
alleviating symptoms? 
What is the anchoring point for judging worsening•	 ? 
Are thresholds of detection different for improvement  •	
and worsening?
The OMERACT “flare” group is conducting a rigorous 
qualitative research study to explore the meaning of flare from 
the patient perspective, comprising 15 focus groups of RA 
patients. Although data collection and analysis are still ongoing, 
it is already clear that flare has many different meanings and 
contexts for individuals, and that our existing, rather loose, 
terminology may not capture the different nuances important 
to patients. Emerging data have yet to be confirmed in the full 
data set; however, for the patient, flare appears to be a multi-
layered and complex phenomenon, set against a background 
of “normal” fluctuating disease activity. Patients’ experiences 
of their disease in flare may include more than physical 
symptoms and could encompass systemic features; “flare” may 
even be preceded by subtle warning signs. Therefore, our data 
thus far suggest that patient-focused variables encompassing 
disease worsening may not be adequately reflected within 
current core sets that are used in randomized controlled trials 
or observational studies. It is clear that patients’ participation 
will be a critical element to define worsening, to develop 
acceptable and understandable language to capture flare, and to 
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test definitions for MDD and MCID. In establishing the “truth” 
of any definition to capture flare, its face validity requisitely 
depends on the incorporation of the patient perspective.
There is also a timely and important opportunity to use 
newly established questionnaires developed by other groups to 
explore the symptoms most sensitive in detecting a flare. Such 
efforts are being led through the Patient-Reported Outcomes 
Measurement Information System (PROMIS) initiative by 
the US National Institutes of Health (NIH), with additional 
work ongoing for harmonization through the World Health 
Organization (WHO) [13,14]. 
Flares in clinical research
Data from which many initial guidelines are developed and/or 
validated come from the analysis of cohorts and longitudinal 
observational studies of patients with RA, increasing their 
generalizability. Longitudinal observational studies usually 
provide data on disease improvement using the same outcome 
measures. However, some may also contain important 
information to aid in a better understanding of disease 
worsening, although there are limited published data on disease 
worsening thus far. In the absence of a gold standard to define 
a flare, studies have used physician decision to change or add 
therapy as a surrogate. In one of these studies, Yaziki et al. 
retrospectively reviewed charts from RA patients and examined 
the numbers of patients in whom a physician had noted a “flare” 
or in whom a change in medications was instituted in the context 
of comparing patients who were receiving etanercept with those 
who were not. They demonstrated that this drug led to fewer 
patients having a flare over the period of observation [15]. In 
another abstract, the CORRONA (Consortium of Rheumatology 
Researchers of North America, Inc.) database was examined for 
worsening in core set measurements leading up to a decision to 
increase therapy [16]. In this study, the sensitivity and specificity 
of various measurements of disease activity (e.g. patient global 
assessment and CDAI) were examined. For example, relative to 
a change in therapy, patient global assessment of disease activity 
was among the better measures with the highest sensitivity and 
specificity [16]. A similar approach is being undertaken at King’s 
College London, London, UK, using a database of RA patients 
attending routine clinics. It examines changes in disease activity 
measures when patients/clinicians report a “flare” or “disease 
worsening” as well as factors that are associated with change 
in therapy (Choy, personal communication). These studies 
provide some initial insights into understanding “flare” in clinical 
practice. However, certain difficulties arise in such analyses 
as they often capture data only intermittently and may fail to 
capture persistent worsening over time. Additional analysis is 
needed to better understand whether thresholds for changes in 
medications may be dependent on the starting point of a patient, 
or if their disease duration is a potential factor that weighs into 
a decision to change treatment. Existing longitudinal cohorts are 
also limited by their potential lack of capture of variables that 
may distinctively factor into disease worsening as opposed to 
disease improvement. For example, evaluation of fatigue, which 
was not included in the original core set of RA measurements, 
may not be present in all existing RA registries or cohorts. 
Since the development of the original RA core set, fatigue has 
been increasingly recognized by patients and clinicians as an 
important outcome variable to assess both improvement and 
worsening [17,18].
defining flare for clinical trials
A particularly critical area in need of a definition of flare is in 
the field of clinical trials (Table 1). Outcomes and endpoints 
in clinical trials have traditionally reflected improvement 
from a baseline (e.g. ACR20/50/70 response, or EULAR good 
responder) or, more recently, endpoints have been reflective of 
a low disease activity state (e.g. DAS remission). The validation 
of the component measurements, MDD, and MCID within 
these indices (e.g. HAQ, patient global assessment, patient 
pain, SF-36) has been conducted based on improvement. There 
are only a few examples in adult RA of clinical trials that 
incorporate a definition of flare or disease worsening [19]. 
“In the absence of a gold standard 
to define a flare, studies have used 
physician decision to change or 
add therapy as a surrogate”
Within the confines of a clinical trial, patients who worsen 
or require the addition of DMARDs may be managed in 
different ways. They may be withdrawn from the protocol 
with no further data recorded and their status may be reported 
as withdrawn due to lack of efficacy; they may be rolled over 
to an active treatment arm; or they may be permitted short 
courses of steroids or intra-articular injections and continued in 
the study with an adverse event reported as “RA flare”.
In most circumstances in clinical trials, assessments are 
made based on a single point in time measurement, thus if 
the patient is in the midst of a temporary and self-reversible 
oscillation (either good or bad), the data may not reflect the 
overall trend of their disease activity. Others have documented 
this as “regression to the mean”, and it is an important factor 
that should be considered when interpreting the results of 
clinical trials [20,21]. Similarly to the case for improvement, 
considerations of expected fluctuations will be important to 
understand in the setting of disease worsening. 
The ability to induce significant improvements in disease and 
“remission” leads to the possibility of tapering or discontinuing 
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medication while maintaining a low disease activity state. 
However, the ability to test different withdrawal strategies is 
without a clear regulatory framework. Induction/withdrawal 
and induction/maintenance strategies are commonplace in 
oncological conditions. The opportunity to study these strategies 
will depend on the development of an outcome definition 
for flare that reflects an appropriate degree of worsening to 
differentiate between different treatment arms.
In both juvenile chronic arthritis and in lupus, there are 
examples of “flare” of disease as an outcome [19]. In juvenile 
rheumatoid arthritis (JRA) clinical trials, all patients are initially 
treated with an active medication; subsequently, in only patients 
who respond, there is a randomized withdrawal in which 
one group of patients receives continuation of therapy while 
the other group does not. Survival curves are then used to 
demonstrate differences in time to flare, and numbers of flares, in 
both groups [22–24]. In lupus, different flare definitions have also 
been incorporated into clinical trials. Despite “negative” studies 
of biological agents in SLE [25,26], a recent early success [27] 
indicates the importance of developing a reliable definition of 
flare that can detect change over time. One can envision studies 
for RA in which patients are induced to a state of low disease 
activity or remission, and then randomized to different regimens 
for maintenance of response. Such studies are needed to assist 
practitioners in the day-to-day management of patients.
“Definition of “flare” as an outcome 
measure must reflect an appropriate 
degree of worsening to differentiate 
between treatment arms”
Studies have been conducted in RA in which there was 
medication withdrawal and evaluation of time to flare. We 
have recently summarized the measurements included in a flare 
definition from these clinical trials [19]. In these studies, there 
was no consistent definition of flare in terms of component or 
composite measurements. In several studies, an inversion of 
improvement criteria has been used to define disease worsening 
that leads to a change in therapy. In two studies of infliximab, a 
flare was defined as a ≥50% diminution in a prior improvement 
in combined swollen and tender joints, which then guided an 
increase in infliximab dose [28,29]. Other studies have used 
an inverse of EULAR improvement criteria for response based 
on DAS to define worsening that would lead to a change in 
therapy. In one study, the concept of persistence of disease 
was recognized: patients were required to have a worsening 
of activity that was observed over more than one visit [30]. 
A recent consensus statement on the use of rituximab also 
used similar inverted EULAR criteria to define a flare to guide 
reinfusion of the drug [9]. While inversion of improvement may 
seem a reasonable definition of flare, its performance is best 
when the instrument changes linearly. It is most problematic 
with percentage changes, for example a 20% decrease in tender 
joint count from 16 is a reduction by 3.2 while a 20% increase 
from a baseline of a joint count of 4 is 0.8.
As discussed above, there are significant questions and 
scenarios in which understanding disease flare could help 
to guide clinical decision-making (e.g. timing of reinfusion 
or reinjection of a periodically administered treatment, dose 
escalation, and comparison of maintenance regimens). The 
development of a flare definition for clinical trials will open 
significant opportunities to study such questions of importance, 
to guide clinical practice and improve patient care.
The analysis of biomarkers and their validation with 
clinical endpoints is an area of active investigation [31–33]. 
The traditional framework for biomarker analysis evaluates 
the baseline level of a marker or an early change from baseline 
to predict a later clinical response [34]. In the context of 
disease worsening, there is also an opportunity to examine 
whether early changes in biochemical markers may precede 
the development of overt clinical symptoms, thus providing 
predictive value that may be used to anticipate and to 
potentially intervene in a manner that would avoid or dampen 
a flare.
A final area in which a “flare” definition is needed is in 
the context of adverse event reporting in clinical trials. The 
OMERACT Drug Safety Group recognized that a standardized 
flare definition was lacking – but necessary, in order to more 
accurately capture loss of efficacy withdrawals in clinical 
trials [35]. 
Statistical analyses
In accordance with OMERACT methodology, we will develop 
an outcome measurement of flare for use in clinical trials that 
will fulfill the necessary criteria of truth, discrimination, and 
feasibility. As part of this method, the variable(s) that show the 
most pronounced discriminant capacity will be assessed further 
via quantification of consistency across studies. In order to do 
this, our OMERACT Flare Working Group will use receiver 
operating characteristics (ROC) plots to determine a potential 
threshold to define flare. Changes in disease activity measures at 
“flare” or “worsening” visit, and the previous clinic/study visit, 
will be determined. We will apply an observation-based approach 
involving analysis of existing RA data for which the clinician has 
considered or categorized the patient as either having a flare or 
not, from each of the available proxy variables. The ability to 
detect and discriminate a “flare effect” in study outcomes will 
be evaluated using the standardized response means (SRMs: 
the ratio of the group mean difference to the pooled standard 
deviation of the mean change scores) [36]. Each available 
outcome variable will be handled as the SRM with standard 
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error, for each different RA cohort, then handled using a standard 
meta-analysis approach [37]. The variable having the lowest I2 
value across studies will be considered the most consistent [38]; 
the variable with the largest SRM (on average) will be considered 
the most discriminant [39]. Using simple 2×2 tables with two 
groups according to the presence or absence of a particular sign 
or symptoms, we will calculate the proportions of patients who 
are correctly “diagnosed” by the test. We will calculate various 
sensitivities and specificities, and investigate the best quantitative 
threshold defining a flare. In order to handle multiplicity, a ROC 
curve will be generated based on the full dataset for each of the 
available databases (i.e. studies) for promising outcome variables 
that consistently discriminate a flare.
the oMERACt Flare  
working Group
The sections above introduced some of the many questions that 
arise in assessing disease worsening and flare in RA. Answering 
these questions is not easy, and the answers remain mostly 
unknown. However, they do demonstrate the importance 
of additional research in this area. An OMERACT group of 
interested individuals was established in 2006 to begin examining 
the area of flare. The initial work of the group has been reported 
[19]. The group has now grown to more than 30 members who 
participate in various working groups, regular teleconferences, and 
face-to-face meetings. An extensive research agenda is underway 
to address the many aspects of flare with the participation of 
clinical researchers in rheumatology, epidemiologists, patient 
representatives, regulators, and pharmaceutical companies, 
taking advantage of the unique perspectives that each of the 
participants represents. In the last year, significant progress has 
been made to evaluate longitudinal observational studies, with 
the examination of pharmaceutical clinical trial data underway. 
Multinational patient focus groups are also being conducted 
to incorporate the critical patient perspective, which may not 
currently be captured in existing clinical trials or observational 
studies. It is anticipated that preliminary definitions for flare 
will be tested against existing datasets in the coming year. The 
incorporation of new domains and instruments will then need 
to be tested prospectively in further longitudinal observational 
studies and clinical trials. Using a data-driven Delphi process, the 
group, including clinicians and patients, will develop definitions 
of flare that can be used in future in both clinical trials and for 
clinical care. 
Conclusions
The members of the OMERACT group strongly believe that 
the time has indeed come for flares of RA to be evaluated in 
more detail. Only through such an exercise to provide an 
evidence-based and consensus pilot definition, can we then 
validate such a measure in multiple contexts (such as in existing 
longitudinal observational studies and clinical trial databases), 
then incorporate several such definitions, potentially with 
new domains or instruments, to capture prospective data 
from longitudinal observational studies and randomized 
controlled trials.
Alongside these research goals, there is clearly a need to 
examine the performance (and potential modification) of such 
a definition for clinical practice. The ACR/EULAR group is 
conducting a similar activity to define remission of disease [4]. 
These different exercises will be complementary and allow us to 
move forward in our ability to study different methods of drug 
tapering (e.g. drug A vs. B, dose decrement, frequency decrease), 
study head-to-head interventions in their ability to induce (and 
maintain) remission, and to establish recommendations that 
assist in patient management. Until this work is conducted and 
studied, we will remain in a largely empirical arena, without 
agreement on study designs or definitions. The international 
OMERACT group, currently with representatives from North 
America, the European Union, Australasia, and, importantly, 
including from its inception the active participation of patients, 
is uniquely positioned to conduct this work. Through several 
groups and subgroups, a series of analyses are underway, with 
anticipated publications to follow as we move through the 
process of consensus.
We believe that the time to act is now to develop a definition 
of disease worsening or flare that meets the OMERACT 
standards of Truth, Discrimination, and Feasibility, recognizing 
that there may well be modifications of any definition for 
different purposes. The fact that we have reached a place in the 
care of patients with RA in which we have a pressing need for a 
flare definition, we believe is a very good thing. No longer must 
we only concentrate on improvement from a prior state, but now 
we raise the bar further toward a goal of therapy to prevent or 
lessen periods of disease worsening, and we move closer toward 
permanent remission or even cure of disease as an outcome.
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